Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 22, 2025, titled "Zydus receives final approval from USFDA for Ibuprofen and Famotidine Tablets, 800 mg/26.6 mg".
Press Release Feb 22 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has received final approval from the USFDA for Ibuprofen and Famotidine tablets, which are indicated for the relief of rheumatoid arthritis and osteoarthritis symptoms. The tablets will be manufactured at Zydus Lifesciences Ltd in Ahmedabad.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Feb 14 2025
- Press Release Feb 12 2025
- Press Release Feb 05 2025
- Press Release Jan 30 2025
- Press Release Jan 26 2025
Later from Zydus Lifesciences
- Press Release Feb 26 2025
- Press Release Mar 04 2025
- Press Release Mar 05 2025
- Press Release Mar 10 2025
- Press Release Mar 12 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences